Doughnut Lesion of the Calvaria and Bone Fragility Syndrome

Doughnut lesion of the calvaria and bone fragility syndrome is a rare, inherited bone disease. It causes ring-shaped, sclerotic spots in the skull bones that look like doughnuts on X-ray. It also causes weak bones with many fractures, often beginning in childhood. Doctors now group these problems together under the name calvarial doughnut lesions with bone fragility (CDL). The disorder sits on a spectrum: some people have “just” childhood-onset osteoporosis with skull lesions; others have a more severe form with neonatal fractures, short stature, and spine and limb deformities (spondylometaphyseal dysplasia). Orpha+2NCBI+2

Calvarial doughnut lesions with bone fragility (CDL) is a rare, inherited bone disorder. People develop fragile bones that break more easily, usually from childhood, and distinctive “doughnut-shaped” sclerotic (dense) rings in the skull bones seen on X-rays. Many have low bone mineral density. Some families show dental issues, short stature, or spine and long-bone problems. CDL is most often caused by pathogenic changes in the SGMS2 gene, which alters sphingomyelin metabolism in bone-forming cells; rare families have variants in IFITM5. The condition typically follows autosomal dominant inheritance (one altered copy is enough). Imaging (skull radiographs/CT/MRI), bone density testing, and genetic testing support the diagnosis.

SGMS2 variants disrupt enzymes that make sphingomyelin in cell membranes. This affects osteoblast–osteoclast signaling and bone remodeling, leading to low bone density and the skull’s characteristic ring-like lesions. The clinical spectrum ranges from childhood-onset osteoporosis to a severe form with neonatal fractures and spondylometaphyseal dysplasia. Pathology may involve altered RANKL/OPG signaling and craniofacial development pathways.

Other names

You might see several names that mean the same or nearly the same thing:

• Calvarial doughnut lesions with bone fragility (CDL)

• Familial “doughnut” lesions of the skull

• Calvarial doughnut lesions–bone fragility syndrome (CDL-BFS)

• SGMS2-related osteoporosis (when the gene cause is known)
  These labels all refer to the same rare condition or to spots along the same spectrum, depending on severity. Wikipedia+1

Types

Because this is a spectrum disorder, “types” are best understood by clinical patterns seen in families and patients:

1) Classic CDL (childhood-onset osteoporosis + skull doughnut lesions).
Children develop low bone mineral density and fractures of the long bones and spine. Skull imaging shows ring-like sclerotic lesions. Growth is often near normal. NCBI

2) Severe CDL with spondylometaphyseal dysplasia (CDL-SMD).
This is the heavy end of the spectrum. Fractures can begin in the newborn period. Children may have short stature, long-bone bowing, and marked thickening/sclerosis of the skull. NCBI+1

3) Mild/attenuated adult form.
Some adults come to attention later with low bone mass, back pain from vertebral fractures, or incidental skull lesions on imaging. The features are milder than in childhood-onset disease. Frontiers

4) SGMS2-negative, IFITM5-variant phenocopy (very rare).
A single family with a specific IFITM5 variant showed similar skull lesions with bone fragility, so clinicians keep it in mind when genetic tests for SGMS2 are negative. Wikipedia

Causes

The main cause is a change (pathogenic variant) in the SGMS2 gene, which encodes sphingomyelin synthase-2, a key enzyme for building cell membranes in bone cells. This disrupts mineralization and bone strength. The list below separates the primary cause from known modifiers that can shape how severe the condition becomes.

1. Pathogenic variants in SGMS2 (autosomal dominant). This is the central, proven cause. Frontiers+1

2. Nonsense SGMS2 variants (for example p.Arg50Ter) that truncate the enzyme. PubMed

3. Missense SGMS2 variants that change key amino acids and impair enzyme function. Wikipedia

4. De novo SGMS2 variants (new in the child, not present in parents), explaining sporadic cases. Frontiers

5. Autosomal dominant inheritance in many families (one altered copy is enough). ScienceDirect

6. Disrupted sphingomyelin synthesis in osteoblasts/osteocytes, weakening bone matrix. Frontiers

7. Abnormal osteocyte lacunocanalicular network, which impairs bone quality. ResearchGate

8. High osteoclast activity reported in biopsy in some families, tipping balance toward bone loss. Wikipedia

9. Abnormal cortical thinning and trabecular structure on pathology, reducing strength. Wikipedia

10. Cranial bone remodeling defects that form ring-like sclerotic “doughnuts.” Radiopaedia

11. IFITM5 variant (p.N48S) in a single family producing a similar phenotype (phenocopy). Wikipedia

12. Genetic background (other common variants) that may modify severity person-to-person. Frontiers

13. Mechanical stress on weak vertebrae and long bones, promoting fractures. (Mechanistic inference consistent with osteoporosis.) Frontiers

14. Delayed diagnosis leading to repeated fractures before treatment, worsening deformity. NCBI

15. Low calcium or vitamin D status can worsen any osteoporosis, including monogenic forms. (General bone health principle applied to CDL.) Frontiers

16. Cranial sclerosis in severe phenotypes, which reflects remodeling imbalance in the skull. NCBI

17. Pubertal growth spurts can unmask fragility because bones are under more load. (General pediatric osteoporosis principle applied to CDL.) Frontiers

18. Pregnancy and lactation may add extra calcium demands and stress in affected adults. (General osteoporosis modifier; consider carefully in monogenic forms.) Frontiers

19. Coexisting endocrine or nutritional issues (e.g., thyroid disease, malabsorption) can amplify bone loss even when SGMS2 is the driver. (General modifier.) Frontiers

20. Limited access to specialist care and imaging delays targeted support and fracture prevention. (Health-system modifier.) NCBI

Symptoms and signs

1. Recurrent bone fractures. Many children break bones with minor trauma; the spine and long bones are common sites. NCBI

2. Low bone mineral density (BMD). DXA scans show low Z-scores for age. NCBI

3. Doughnut-shaped skull lesions. Circular sclerotic rings on calvarial imaging are the hallmark. Radiopaedia

4. Back pain and height loss. Vertebral compression fractures can cause pain and loss of height. NCBI

5. Long-bone deformities. Repeated fractures can lead to bowing or angular deformity, especially in severe cases. Frontiers

6. Short stature (severe end). When fractures start in the neonatal period, growth can be reduced. NCBI

7. Cranial sclerosis. Parts of the skull can show abnormally dense bone, especially in severe cases. NCBI

8. Spine changes of spondylometaphyseal dysplasia. The vertebrae and metaphyses can look dysplastic on X-ray. NCBI

9. Dental issues. Some patients have enamel hypoplasia, caries, or abnormal tooth development. Wikipedia

10. Raised alkaline phosphatase (sometimes). This bone turnover marker can be high in some patients. Wikipedia

11. Juvenile open-angle glaucoma (rare association). Reported in one large SGMS2 family; eye screening is reasonable when there are visual symptoms. IOVS

12. Facial nerve palsy or neurologic features (occasional). A few patients show neurologic involvement in the SGMS2 spectrum. Frontiers

13. Scoliosis. Sideways curvature of the spine can appear from vertebral fragility. Wikipedia

14. Muscle pain or fatigue after fractures. These are common secondary effects of repeated injuries. NCBI

15. Incidental discovery. Some adults learn about the condition only when a skull image is taken for another reason and shows the classic rings. Radiopaedia

Diagnostic tests

A) Physical examination

1. General growth and body build. The clinician records height, weight, and body proportions. Short stature and limb deformities point to a severe phenotype. NCBI

2. Spine inspection and palpation. Loss of height, tenderness, or kyphosis suggests vertebral compression fractures. NCBI

3. Gait and limb alignment. Bowing or limp after previous long-bone fractures hints at chronic fragility. Frontiers

4. Head and cranial exam. Palpation may suggest areas of thickened skull; imaging confirms doughnut lesions. Radiopaedia

B) Manual/bedside orthopedic tests

5. Functional mobility tests (sit-to-stand, timed up-and-go). These simple checks show pain-limited mobility and risk after fractures. They guide rehab needs. Frontiers

6. Spine percussion test. Gentle percussion over vertebrae can reproduce pain in compression fractures; imaging then confirms. NCBI

7. Range-of-motion assessment. Restricted hip/shoulder motion may follow healed fractures or deformities and needs therapy. Frontiers

8. Balance testing. Poor balance increases fall risk in fragile bones; it directs prevention strategies. Frontiers

C) Laboratory and pathological tests

9. Serum calcium, phosphate, alkaline phosphatase, PTH, and 25-OH vitamin D. These baseline studies assess bone metabolism and rule out other causes of osteoporosis. ALP may be elevated in some CDL patients. Wikipedia

10. Bone turnover markers (e.g., P1NP, CTX). They help describe formation vs. resorption and follow responses over time, though data are limited in CDL. Frontiers

11. Genetic testing for SGMS2. Next-generation sequencing or a targeted panel can confirm the molecular diagnosis and guide family testing. NCBI

12. IFITM5 testing if SGMS2 is negative and phenotype fits. Rare phenocopy families make this a reasonable second-line test. Wikipedia

13. Bone biopsy (selected cases). Reports show thin cortex, altered trabeculae, and high osteoclast activity in some families; biopsy is not routine but can clarify pathology. Wikipedia

14. Dental exam and enamel evaluation. Because tooth defects occur in some patients, dental review adds supportive evidence and helps with care. Wikipedia

D) Electrodiagnostic and related physiologic tests

15. Nerve conduction studies/EMG (only if facial nerve palsy or neuropathic symptoms are present). Some SGMS2-related cases include neurologic features, so targeted testing can help. Frontiers

16. Ocular electrophysiology (ERG/VEP) and visual field testing if glaucoma or visual symptoms are present, as reported in a large SGMS2 family. IOVS

17. Densitometric vertebral fracture assessment (VFA) with DXA is an imaging-linked physiologic tool that screens for silent vertebral crush fractures in fragile bone. NCBI

E) Imaging tests

18. Skull X-ray. Shows classic ring-like (“doughnut”) sclerotic lesions with/without a central density. This is the signature finding. Radiopaedia

19. CT of the skull. Defines lesion edges and sclerosis better than plain X-ray when diagnosis is uncertain. Radiopaedia

20. MRI of the skull. Helps assess marrow and soft tissue around the lesions when needed; used in case series. Wikipedia

21. DXA scan (lumbar spine, total body less head in children). Confirms low BMD and tracks response to therapy or growth. NCBI

22. Full skeletal survey (X-ray series). Looks for other fractures or bone deformities in severe phenotypes. NCBI

23. Spine radiographs. Detect and monitor compression fractures over time. NCBI

24. Orthopantomogram and dental imaging. If dental enamel problems are suspected, imaging supports diagnosis and dental planning. Wikipedia

Non-pharmacological treatments (therapies & other care)

Each item includes a brief description (aimed ~150 words where helpful), the main purpose, and the key mechanism/rationale.

1. Fracture-smart daily living program
   Description: Teach simple routines that lower fall and fracture risk: careful transfers, non-slip shoes, using rails, safe lifting, and pacing activity. Provide home safety checks (remove loose rugs, improve lighting). Purpose: Fewer falls and less force transmitted to fragile bones. Mechanism: Environmental and behavioral changes reduce fall probability and impact loads on bone.

2. Targeted physiotherapy (gentle, progressive)
   Description: Supervised, low-impact strengthening of lower-limb, trunk, and hip muscles; posture and balance drills; aquatic therapy when available. Purpose: Improve balance, muscle support of skeleton, walking confidence, and pain control. Mechanism: Stronger muscles and better balance reduce falls and decrease mechanical stress on weak bones and vertebrae.

3. Occupational therapy & assistive devices
   Description: OT evaluates school/work/home tasks, recommends reachers, cushioned seating, light-weight tools, and graded activity plans. Purpose: Preserve independence while avoiding overload that triggers fractures. Mechanism: Task adaptation reduces peak strain and repetitive micro-trauma on osteoporotic bone.

4. Spinal posture and back-care education
   Description: Teach neutral-spine mechanics, log-rolling, and safe bending (hip-hinge). Purpose: Lower vertebral compression risk and chronic back pain. Mechanism: Reducing flexion/twist moments cuts compressive loads on weakened vertebrae.

5. Protective bracing (selected cases)
   Description: Temporary braces for painful vertebral compression or healing long-bone fractures; custom cranial protection if lesions are tender/expansile and risk of impact exists. Purpose: Stabilize healing bone and reduce pain during higher-risk activities. Mechanism: External support lowers bending/axial loads while tissue heals.

6. Guided weight-bearing & balance training
   Description: Individually-titrated weight-bearing (walking, step-ups), tandem stance, and perturbation balance work under supervision. Purpose: Build bone-protective muscle and neuromotor control safely. Mechanism: Moderate, controlled loading stimulates osteoblast activity without overload.

7. Pain self-management (non-drug)
   Description: Heat/ice, relaxation, pacing, sleep optimization, mindfulness, and graded activity plans. Purpose: Reduce pain flares and fear-of-movement that worsens deconditioning. Mechanism: Behavioral pain strategies reduce central sensitization and allow safe re-activation.

8. Nutrition counseling (adequate calcium & vitamin D)
   Description: Plan meals to reach age-appropriate calcium targets and safe vitamin D intake; reinforce sunlight hygiene where applicable. Purpose: Provide raw materials for mineralization and maintain calcium balance. Mechanism: Calcium and vitamin D work together to support bone remodeling and mineral deposition.

9. Dental surveillance & enamel/dentin care
   Description: Regular dental checks and fluoride/enamel care when dentinogenesis issues exist; manage caries early. Purpose: Prevent painful dental complications that are reported in some CDL families. Mechanism: Early dental care addresses enamel/dentin fragility often noted with SGMS2 disorders.

10. Genetic counseling for the family
    Description: Explain autosomal dominant inheritance, variable severity, options for family testing, and reproductive planning. Purpose: Informed decisions and early monitoring in at-risk relatives. Mechanism: Identifying carriers enables anticipatory guidance and fracture-prevention education.

11. School/work accommodations
    Description: Allow elevator use, modified PE, ergonomic seating, and flexible schedules after fractures. Purpose: Reduce re-injury, maintain participation. Mechanism: Lowering mechanical stress and fatigue reduces fracture risk while supporting quality of life.

12. Home exercise kit (thera-band, step, mat)
    Description: A simple kit and printed routine to continue clinic exercises at home. Purpose: Maintain gains between therapy visits. Mechanism: Regular submaximal loading sustains muscle and balance benefits.

13. Vision screening (selected families)
    Description: Check for glaucoma or vision issues reported in some pedigrees. Purpose: Prevent fall risk and treat ocular problems early. Mechanism: Correcting vision reduces falls; glaucoma surveillance addresses reported association.

14. Fall-safe footwear & floor strategy
    Description: Non-skid soles, tidy cords, night lights. Purpose: Reduce slips at home. Mechanism: Environmental control is a proven fall-risk reducer in fragility bone care.

15. Sunlight hygiene for vitamin D
    Description: Short, regular, safe sunlight exposure as appropriate. Purpose: Support vitamin D status when diet is insufficient. Mechanism: Cutaneous vitamin D3 synthesis supports calcium absorption.

16. Smoking cessation & alcohol moderation
    Description: Brief counseling and referral programs. Purpose: Improve bone health and healing. Mechanism: Smoking and excess alcohol impair osteoblasts and increase fracture risk.

17. Body-weight management & protein adequacy
    Description: Balanced diet to avoid severe under- or over-nutrition; adequate protein. Purpose: Support muscle and bone remodeling. Mechanism: Protein provides collagen matrix; healthy weight lowers mechanical extremes.

18. Activity modification during healing
    Description: Temporary restriction of impact, with a plan to re-load gradually. Purpose: Prevent refracture. Mechanism: Controlled mechanobiology: enough load for healing, not enough to re-injure.

19. Psychological support
    Description: Coping skills, peer groups, and family counseling after recurrent fractures. Purpose: Reduce anxiety and improve adherence to care. Mechanism: Better self-efficacy improves safe activity and rehab participation.

20. Regular DXA and imaging surveillance
    Description: Schedule bone density checks and targeted skull/spine imaging as advised. Purpose: Track bone status and lesion behavior to adjust therapy. Mechanism: Objective monitoring guides timing of pharmacologic or surgical steps.

---

Drug treatments

CDL has no drug “specific” cure; clinicians use osteoporosis agents to improve bone mass and reduce fracture risk. Doses/indications below reflect FDA labeling for osteoporosis; pediatric/rare-disease use can be off-label and needs specialist oversight.

1) Alendronate (Fosamax)
Class: Bisphosphonate (oral). Dose/Time: 70 mg once weekly (adult osteoporosis label). Purpose: Reduce fractures by suppressing bone resorption. Mechanism: Binds hydroxyapatite; inhibits osteoclasts → increases BMD. Side effects: GI irritation, esophagitis, musculoskeletal pain; rare ONJ/atypical femur risk. Evidence note: Label shows reduced bone turnover markers and antifracture data in postmenopausal osteoporosis.

2) Risedronate (Actonel/Atelvia)
Class: Bisphosphonate (oral; immediate or delayed-release). Dose/Time: 35 mg weekly (Actonel) or 35 mg DR weekly after breakfast (Atelvia). Purpose/Mechanism: As above. Side effects: Upper-GI irritation; remain upright after dose; rare ONJ/atypical femur. Label cautions: Do not use Actonel and Atelvia together; follow dosing posture rules.

3) Ibandronate (Boniva)
Class: Bisphosphonate (oral monthly 150 mg; IV 3 mg q3mo). Purpose/Mechanism: Osteoclast inhibition; increases BMD, reduces vertebral fractures. Adverse effects: Flu-like acute-phase reactions (IV), GI irritation (oral), rare ONJ/atypical femur.

4) Zoledronic acid (Reclast)
Class: Bisphosphonate (IV). Dose/Time: 5 mg IV once yearly (adult osteoporosis). Purpose/Mechanism: Potent osteoclast inhibition. Key label points: Ensure calcium/vitamin D; watch for hypocalcemia; renal precautions. Adverse effects: Flu-like reaction, hypocalcemia risk, rare ONJ/atypical femur.

5) Pamidronate (Aredia)
Class: Bisphosphonate (IV). Note: Not pediatric-labeled for OI/fragility in the U.S., but used off-label in children internationally. Purpose/Mechanism: Osteoclast inhibition with BMD gains reported in OI literature. Adverse effects: Acute-phase reaction; renal dosing considerations.

6) Denosumab (Prolia)
Class: RANKL inhibitor (SC). Dose/Time: 60 mg SC every 6 months (adult indications). Purpose: Reduce vertebral, non-vertebral, and hip fractures in high-risk osteoporosis. Mechanism: Blocks RANKL → suppresses osteoclast formation/activity. Adverse effects: Hypocalcemia, infections, dermatitis/eczema, rare ONJ/atypical femur; consider rebound bone loss if stopped without transition.

7) Teriparatide (Forteo / teriparatide injection)
Class: PTH(1-34) anabolic. Dose/Time: 20 mcg SC daily; lifetime duration limits per label. Purpose: Build bone and reduce fractures in very high-risk patients. Mechanism: Intermittent PTH stimulates osteoblasts → rapid BMD gains. Adverse effects: Transient hypercalcemia, dizziness, nausea; osteosarcoma boxed warning removed but risk language remains in some materials—follow latest label.

8) Abaloparatide (Tymlos)
Class: PTHrP analog anabolic. Dose/Time: 80 mcg SC daily, limited duration. Purpose/Mechanism: Stimulates bone formation with antifracture benefit. Adverse effects: Dizziness, palpitations, hypercalciuria; similar duration cautions.

9) Romosozumab (Evenity)
Class: Sclerostin inhibitor (bone-forming + antiresorptive). Dose/Time: 210 mg SC monthly for 12 doses maximum, then switch to antiresorptive. Purpose: Rapid BMD increase and vertebral fracture risk reduction. Key caution: Boxed warning for MI/stroke risk—avoid if recent CV events.

10) Raloxifene (Evista)
Class: SERM (oral). Dose/Time: 60 mg daily. Purpose: Vertebral fracture risk reduction in postmenopausal women; breast cancer risk reduction benefit in some contexts. Adverse effects: Hot flashes, leg cramps; VTE risk.

11) Calcitonin-salmon (Miacalcin/Fortical)
Class: Calcitonin (nasal or injection). Purpose: Limited role; vertebral pain relief in acute fractures; fracture efficacy is modest; labels warn about possible malignancy signal—reserve for when alternatives aren’t appropriate. Adverse effects: Rhinitis (nasal), hypersensitivity; hypocalcemia risk.

12) Conjugated estrogens ± progestin (Premarin / Prempro)
Class: Estrogen (± progestin). Purpose: Prevention of postmenopausal osteoporosis when non-estrogen options are unsuitable; use lowest dose for shortest time for menopausal indications. Risks: VTE, stroke, breast/uterine cancer considerations—specialist counseling required.

13) Conjugated estrogens/bazedoxifene (Duavee)
Class: Estrogen + SERM combination. Purpose: Menopausal symptoms and prevention of postmenopausal osteoporosis; VTE/stroke warnings apply. Mechanism: Estrogen effects on bone with endometrial protection by bazedoxifene.

14) Zoledronic acid (Zometa)
Class: IV bisphosphonate (oncology dosing). Note: Same active ingredient as Reclast; do not co-administer with other bisphosphonates. Relevance: Used for other bone conditions; listing here reminds about ingredient overlap and precautions.

15) (Re-emphasis) Denosumab biosimilar entries
New denosumab labeling clarifies indications/adverse effects across populations; transitions off denosumab need planning to prevent rebound vertebral fractures—specialist management is essential.

16)–20) Specialist-directed choices
Depending on age/sex, fracture pattern, and comorbidities, teams individualize among the above core agents (anti-resorptive vs anabolic) and sequence therapy (e.g., romosozumab → alendronate). Because CDL is rare, medication choice follows general osteoporosis evidence while monitoring skull lesions and whole-skeleton fragility. (See evidence and precautions in the labels cited above.)

Important: Pediatric use of many agents is off-label; dosing and risks require a metabolic bone specialist.

---

Dietary molecular supplements

Supplements are adjuncts, not cures. Discuss with your clinician to individualize dosing and avoid interactions.

1. Vitamin D3 (cholecalciferol)
   What it does: Helps the gut absorb calcium and supports mineralization. Mechanism: Increases intestinal calcium/phosphate absorption and regulates PTH. Typical dosing: Individualized to keep 25(OH)D in sufficiency; many adults need 600–800 IU/day, sometimes more based on levels and clinician advice. Note: Excess can cause hypercalcemia.

2. Calcium (diet first; supplement if needed)
   Function: Structural mineral for bone; works with vitamin D. Mechanism: Supplies hydroxyapatite; sufficient intake prevents secondary hyperparathyroidism. Dosing: Age-specific targets (e.g., 1,000–1,200 mg/day for most adults; higher in teens/older adults), preferably from food.

3. Vitamin K2 (menaquinone-7, MK-7)
   Function: Carboxylates osteocalcin, helping bind calcium to bone. Mechanism: Improves ratio of carboxylated to uncarboxylated osteocalcin. Evidence: Meta-analyses suggest maintaining/improving lumbar spine BMD in older adults. Dosing: Varies by product; discuss with clinician, especially if on anticoagulants.

4. Magnesium
   Function: Cofactor in bone formation and vitamin D/PTH metabolism. Mechanism: Influences osteoblast/osteoclast activity. Evidence: Population studies link higher intake with higher BMD. Dosing: Meet RDA via foods; supplement if deficient.

5. Protein (adequate dietary intake)
   Function: Provides amino acids for collagen matrix. Mechanism: Supports bone formation and muscle preservation. How: Distribute protein through the day; pair with calcium-rich foods.

6. Omega-3 fatty acids
   Function: Anti-inflammatory milieu may support bone turnover balance. Mechanism: Modest effects via cytokine pathways; food sources preferred (fish). Note: Evidence is mixed; use as part of heart-healthy diet.

7. Boron (trace element)
   Function: May influence calcium and vitamin D metabolism and bone formation. Mechanism: Modulates steroid hormones and mineral handling; evidence not definitive. Caution: Not an essential nutrient; avoid high doses.

8. Collagen peptides (dietary protein form)
   Function: Source of glycine/proline for collagen matrix; may aid joint discomfort. Mechanism: Provides substrate for collagen synthesis; evidence modest. Use: As part of overall protein strategy.

9. Silicon (e.g., orthosilicic acid in foods)
   Function: May support connective tissue and bone matrix maturation. Mechanism: Putative role in collagen cross-linking; evidence preliminary. Approach: Emphasize food sources (whole grains, some waters).

10. Zinc (if deficient)
    Function: Cofactor for enzymes in bone formation. Mechanism: Supports osteoblast activity; deficiency impairs growth. Approach: Aim for dietary adequacy; supplement only if low.

---

Regenerative / stem-cell / immune-support drug

These are conceptual or specialist-directed and may be off-label or investigational in pediatric rare bone disease. Always involve a metabolic bone center.

1. Teriparatide (anabolic bone builder) – Intermittent PTH drives new bone formation; useful in very high fracture risk adults; sequencing after antiresorptives may maximize gains.

2. Abaloparatide (anabolic) – PTHrP analog with rapid spine BMD gains; limited total treatment duration, then transition to antiresorptive.

3. Romosozumab (bone-forming biologic) – Sclerostin inhibition produces fast BMD rise; requires cardiovascular risk screening and a follow-on antiresorptive.

4. Denosumab (RANKL antibody) – Potent antiresorptive; consider “exit strategy” to avoid rebound bone loss.

5. Bisphosphonate cycles in children (specialist-guided) – IV pamidronate or zoledronic acid can reshape vertebrae and improve BMD in OI cohorts; pediatric use is off-label in the U.S.

6. Cell/gene-targeted therapies (future direction) – No approved stem-cell or gene therapy exists for CDL; care focuses on bone strength and fracture prevention while research advances in monogenic osteoporosis.

---

Surgeries (what is done and why)

Intramedullary rodding of long bones – Straightens bowed bones and prevents repeat fractures; improves function in severe deformity patterns. Used widely in OI and extrapolated where fragility and deformity coexist.

Vertebral intervention (selected cases) – Bracing first; refractory painful vertebral compression may prompt specialist procedures; decision is highly individualized in children.

Fracture fixation with low-profile implants – Standard orthopedic care for displaced fractures; minimize immobilization time to avoid deconditioning.

Cranial lesion biopsy/excision (rare/atypical) – If a calvarial lesion is atypical, expanding, or symptomatic, neurosurgical evaluation may consider biopsy or excision to confirm pathology and relieve symptoms.

Corrective osteotomy – For recurrent malalignment affecting function or causing repeated fractures, guided by pediatric/orthopedic teams.

---

Prevention

1. Keep up with supervised strength/balance work.

2. Make the home fall-safe (lighting, rugs, cords).

3. Meet calcium and vitamin D targets (food first).

4. Don’t smoke; limit alcohol.

5. Use proper lifting/bending (hip-hinge).

6. Wear supportive, non-slip footwear.

7. Keep vision corrected; consider glaucoma checks if family reports exist.

8. Maintain healthy body weight and adequate protein.

9. Continue dental checkups to protect enamel/dentin.

10. Attend scheduled DXA/imaging reviews to adjust care.

---

When to see a doctor (red flags)

• New fracture or suspected fracture pain, sudden back pain suggesting vertebral compression, or head injury over a skull lesion.

• Worsening headaches, scalp tenderness, or enlarging skull bumps.

• Signs of low calcium (tingling, cramps) after starting antiresorptives or denosumab.

• Dental pain, gum problems, or planned invasive dental work while on potent antiresorptives (to discuss ONJ risk).

• Before starting, stopping, or switching bone medicines—especially denosumab (rebound risk without a transition plan).

---

Foods to eat vs. avoid

Eat more:

• Dairy or fortified alternatives (milk, yogurt) for calcium.

• Leafy greens, beans, and almonds (extra calcium/magnesium).

• Oily fish and eggs (vitamin D and protein).

• Protein with every meal (supports bone matrix and muscle).

• Whole foods rich in vitamin K (leafy greens) and silicon (whole grains).

Limit/avoid:

• Very high salt and ultra-processed foods (increase urinary calcium loss).

• Sugary drinks in place of milk/fortified choices.

• Excess alcohol (bone and fall risk).

• Smoking/tobacco (harms bone and healing).

• “Megadose” supplements without testing/plan (risk of hypercalcemia or interactions).

---

FAQs

1) Is CDL the same as common osteoporosis?
No. CDL is a genetic bone fragility disorder with distinctive skull “doughnut” lesions and usually begins in childhood, while common osteoporosis is usually age- or hormone-related.

2) Which gene is most often involved?
SGMS2 is most common; rarely, IFITM5 variants can mimic the phenotype.

3) How is CDL inherited?
Autosomal dominant—one altered copy can cause disease; family counseling is useful.

4) How do doctors find the skull lesions?
Skull X-rays/CT or MRI show ring-like sclerotic lesions (“doughnuts”).

5) Can medicines cure CDL?
No cure, but osteoporosis therapies (anti-resorptives or anabolics) can improve BMD and lower fracture risk in appropriate patients under specialist care.

6) Are bisphosphonates used in children?
They are widely used off-label for pediatric bone fragility (e.g., OI) with documented BMD and symptom benefits, but U.S. labeling varies; specialist guidance is required.

7) What about denosumab?
Effective antiresorptive in adults at high fracture risk; needs calcium/vitamin D repletion and a planned transition when stopping to avoid rebound fractures.

8) Do anabolic drugs help?
Agents like teriparatide or abaloparatide, and romosozumab (bone-forming biologic), can rapidly increase BMD in very high-risk adults, with label-specific limits and cautions.

9) Will helmets help for scalp tenderness?
Custom protective solutions may help during high-risk activities; discuss with your team if skull lesions are symptomatic.

10) Do I still need calcium and vitamin D on medicine?
Yes—labels for IV bisphosphonates and denosumab emphasize maintaining calcium/vitamin D.

11) Are calcitonin nasal sprays recommended?
They have limited roles and cancer-signal warnings on labels; reserved for situations where alternatives are unsuitable.

12) How often should BMD be checked?
Your specialist will schedule DXA at intervals (often every 1–2 years) to track response and adjust therapy.

13) Can CDL present with normal BMD?
Phenotypic variability exists—even paradoxically high BMD has been reported with some SGMS2 variants; clinical judgment remains key.

14) Is surgery common?
Most care is medical + rehab; surgery is for deformity, unstable fractures, or atypical skull lesions causing symptoms.

15) What specialists should be involved?
A metabolic bone specialist, geneticist, orthopedist, dentist, physiotherapist, and (when needed) neurosurgeon for atypical skull lesions.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 08, 2025.

PDF Documents For This Disease Condition References